Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.91 |
| ▸ | BLM | P54132 | 1/20 | 0.91 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.91 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | INPPL1 | O15357 | 2/20 | 0.35 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.35 |
| ▸ | INPP5B | P32019 | 1/20 | 0.35 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.35 |
| ▸ | ITPR3 | Q14573 | 3/20 | 0.33 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.33 |
| ▸ | ITPR2 | Q14571 | 1/20 | 0.33 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrophosphoric Acid SCHEMBL8851914 | 0.95 | FDPS (1.00) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL29634664 | 0.95 | — | — | |
| Pyrophosphoric Acid SCHEMBL292348 | 0.95 | FDPS (1.00) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL3654 | 0.95 | — | — | |
| Pyrophosphoric Acid SCHEMBL23537580 | 0.91 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL11596222 | 0.91 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL119136 | 0.91 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL21145230 | 0.91 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL21433694 | 0.91 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL19281702 | 0.91 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026838-A1 | METHODS OF PREVENTING PROTEIN AGGREGATION | TRUEBINDING, INC. | 2025-01-23 | — | — | US | claimed |
| EP-4370555-A1 | METHODS OF PREVENTING PROTEIN AGGREGATION | TrueBinding, Inc. (US) | 2024-05-22 | — | — | EP | claimed |
| CN-117916269-A | Method for preventing aggregation of proteins | 真和制药有限公司 | 2024-04-19 | — | — | CN | claimed |
| WO-2023288252-A1 | METHODS OF PREVENTING PROTEIN AGGREGATION | TRUEBINDING, INC. (US) | 2023-01-19 | — | — | WO | claimed |
| EP-3814376-A1 | TRANSTHYRETIN ANTIBODIES AND USES THEREOF | Mor Research Applications Ltd. (IL) | 2021-05-05 | — | — | EP | claimed |
| EP-3814376-B1 | TRANSTHYRETIN ANTIBODIES AND USES THEREOF | MOR RESEARCH APPLIC LTD (IL) | 2025-09-03 | — | — | EP | disclosed |
| US-12358973-B2 | Transthyretin antibodies and uses thereof | MOR RESEARCH APPLICATIONS LTD. (IL) | 2025-07-15 | — | — | US | disclosed |
| US-20250101416-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF TRANSTHYRETIN AMYLOIDOSIS | ACCUREDIT THERAPEUTICS SUZHOU CO LTD (CN) | 2025-03-27 | — | — | US | disclosed |
| EP-4499829-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF TRANSTHYRETIN AMYLOIDOSIS | Accuredit Therapeutics (Suzhou) Co., Ltd. (CN) | 2025-02-05 | — | — | EP | disclosed |
| US-20250026838-A1 | METHODS OF PREVENTING PROTEIN AGGREGATION | TRUEBINDING, INC. | 2025-01-23 | — | — | US | disclosed |
| US-20250002568-A1 | TRANSTHYRETIN ANTIBODIES AND USES THEREOF | MOR RESEARCH APPLICATIONS LTD. (IL) | 2025-01-02 | — | — | US | disclosed |
| CN-118974256-A | Compositions and methods for treating transthyretin amyloidosis | 锐正基因(苏州)有限公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20040213756-A1 | Delivering a structurally reinforcing agent to a ventricle comprising solid material to increase compliance; preventing thinning of ventricular infarct zone; crosslinked collagen; pro-fibroblastic and angiogenic agents; drug delivery; cardiovascular disorders | ABBOTT CARDIOVASCULAR SYSTEMS INC. | 2004-10-28 | — | — | US | disclosed |
| US-20040208845-A1 | Delivering structurally reinforcing agents into a ventricle to increase compliance; prevention of remodeling and thinning of infarct zone by crosslinking collagen; pro-fibroblastic, antiischemic and angiogenic agents | ABBOTT CARDIOVASCULAR SYSTEMS INC. | 2004-10-21 | — | — | US | disclosed |
| US-6153654-A | PERI-OPERATIVELY ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF AN INTRAVENOUS BETA ADRENERGIC ANTAGONIST THAT INHIBITS TISSUE DAMAGE FROM ISCHENIIA. | HOLTZ RUSSELL R (US) | 2000-11-28 | — | — | US | disclosed |
| WO-1998024381-A1 | METHOD OF IMPROVING OUTCOME OF CARDIOPULMONARY BYPASS SURGERY | HOLTZ RUSSELL R (US) | 1998-06-11 | — | — | WO | disclosed |
| US-4935223-A | PULSING ELECTRICAL FIELD RENDERS MEMBRANE PERMEABLE TO LABELING MATERIAL; ADMINISTERING LABELED CELLS TO A PATIENT AND MONITORING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1990-06-19 | — | — | US | disclosed |
| EP-0065347-B1 | PROCESS AND APPARATUS FOR PURIFYING COMPOSITIONS LABELED WITH TECHNETIUM-99M | UNIVERSITY PATENTS, INC. (US) | 1985-03-20 | — | — | EP | disclosed |
| US-4401646-A | STANNOUS PHTHALATE AND ANTIOXIDANT | UNIVERSITY PATENTS INC. (US) | 1983-08-30 | — | — | US | disclosed |
| EP-0065347-A2 | Process and apparatus for purifying compositions labeled with technetium-99m | UNIVERSITY PATENTS, INC. (US) | 1982-11-24 | — | — | EP | disclosed |